Interstitial Lung Disease News

Doctors from across the world gathered at this year’s American Thoracic Society International Conference in San Diego to present research on various respiratory diseases and conditions.

SAN DIEGO — Six months before dying, patients with COPD and idiopathic pulmonary fibrosis vs. lung cancer had reduced odds for outpatient palliative care, according to a poster at the American Thoracic Society International Conference.

Among patients with idiopathic pulmonary fibrosis, 12-week bexotegrast was deemed well tolerated and may have an antifibrotic effect, according to results published in American Journal of Respiratory and Critical Care Medicine.

SAN DIEGO — Among patients with idiopathic pulmonary fibrosis, twice-daily buloxibutid for 36 weeks significantly improved FVC, according to research presented at the American Thoracic Society International Conference.

SAN DIEGO — Taking an oral lysophosphatidic acid receptor 1 antagonist for 26 weeks slowed time to disease progression in idiopathic pulmonary fibrosis, according to a presentation at the American Thoracic Society International Conference.

SAN DIEGO — After receiving a hedgehog pathway inhibitor for 12 weeks, adults with idiopathic pulmonary fibrosis had better lung function, according to research presented at the American Thoracic Society International Conference.

SAN DIEGO — The absolute change in FVC at 48 weeks was similar between patients with idiopathic pulmonary fibrosis receiving pamrevlumab vs. placebo, according to a presentation at the American Thoracic Society International Conference.

DESTIN, Fla. — Detection and treatment of interstitial lung disease in systemic sclerosis calls for early and aggressive action, according to data presented at the Congress of Clinical Rheumatology East.

The diagnostic yield for interstitial lung disease was comparable between immediate surgical lung biopsy and a strategy that began with transbronchial cryobiopsy, according to results published in The Lancet Respiratory Medicine.

The odds for severe acute respiratory disease events rose among previous/current smokers with evidence of quantitative interstitial abnormality, or QIA, progression on CT scans, according to results published in Radiology.